ROCKVILLE, Md., Oct. 17, 2006 (PRIMEZONE) -- Cytomedix, Inc. (AMEX:GTF) today announced that the Food and Drug Administration’s (FDA or Agency) Center for Biologics Evaluation and Research (CBER) has denied the Company’s claim that AutoloGel(tm) is substantially equivalent to predicate devices, as asserted in the Company’s 510(K) Pre-Market Notification. The FDA has offered the Company the opportunity to have the decision reconsidered as part of its established appeals process and the Company will proceed with an appeal immediately. Kshitij Mohan, Ph.D., Cytomedix Chairman and CEO, will host a conference call and webcast with members of the investment community today, October 17, 2006 at 4:00 p.m. Eastern time to discuss this matter.
